HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Aliskiren in early postnatal life prevents hypertension and reduces asymmetric dimethylarginine in offspring exposed to maternal caloric restriction.

AbstractINTRODUCTION:
Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is involved in hypertension. We tested whether aliskiren treatment in early postnatal life can reduce ADMA and regulate the renin-angiotensin system to prevent hypertension in rat offspring exposed to maternal caloric restriction (CR).
MATERIALS AND METHODS:
Four groups of 12-week-old male offspring were sacrificed: control, CR, CR+aliskiren, and CR+losartan group. The CR group included offspring from 50% food-restricted maternal rats. The CR+aliskiren and CR+losartan groups were produced by treating CR offspring with oral aliskiren 10 mg/kg/day or losartan 20 mg/kg/day between 2-4 weeks of age, respectively.
RESULTS:
Blood pressure increased in CR rats, which was prevented by aliskiren or losartan. CR increased plasma ADMA levels, which aliskiren prevented. Renal renin and prorenin receptor (PRR) expression increased in CR rats treated with aliskiren, whereas both were reduced by losartan. Both aliskiren and losartan decreased renal mRNA expression of angiotensinogen, angiotensin II type 2 receptor, and Mas in CR rats. However, aliskiren increased angiotensin II type 2 receptor and Mas protein levels in CR kidneys.
CONCLUSIONS:
Early aliskiren therapy prevents CR-induced hypertension via ADMA reduction, decreases angiotensinogen expression, and increases renal angiotensin II type 2 receptor and Mas protein.
AuthorsChien-Ning Hsu, Chien-Te Lee, Li-Tung Huang, You-Lin Tain
JournalJournal of the renin-angiotensin-aldosterone system : JRAAS (J Renin Angiotensin Aldosterone Syst) Vol. 16 Issue 3 Pg. 506-13 (Sep 2015) ISSN: 1752-8976 [Electronic] England
PMID24833625 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© The Author(s) 2014.
Chemical References
  • Amides
  • Fumarates
  • aliskiren
  • N,N-dimethylarginine
  • Arginine
  • Peptidyl-Dipeptidase A
  • Ace2 protein, rat
  • Angiotensin-Converting Enzyme 2
  • Histone Deacetylases
  • Losartan
Topics
  • Amides (pharmacology, therapeutic use)
  • Angiotensin-Converting Enzyme 2
  • Animals
  • Animals, Newborn
  • Arginine (analogs & derivatives, blood)
  • Blood Pressure (drug effects)
  • Blotting, Western
  • Body Weight (drug effects)
  • Caloric Restriction
  • Female
  • Fumarates (pharmacology, therapeutic use)
  • Gene Expression Regulation (drug effects)
  • Histone Deacetylases (metabolism)
  • Hypertension (drug therapy, prevention & control)
  • Losartan (pharmacology)
  • Male
  • Peptidyl-Dipeptidase A (metabolism)
  • Rats, Sprague-Dawley

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: